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Abstract
Background: Women with acute uncomplicated urine infection are usually treated with antibiotics. One trial has
demonstrated that delayed antibiotic treatment offered without symptom relief results in a modest reduction in
antibiotic use. There is some evidence that ibuprofen provides symptom relief and reduces antibiotic use. Uva-ursi,
a herbal product, has a traditional use for urinary infection symptom relief. We set out to test: in adult women with
suspected UTI who accept the delayed prescription strategy: Do NSAIDs or uva-ursi (a herbal product) provide relief
from urinary symptoms and reduce antibiotic use.
Methods/design: Adult women with suspected urinary tract infection presenting to primary care will be randomised
using a factorial trial design in which patients will be randomised to one of two interventions as below:
Group 1 – Uva-ursi + advice to take ibuprofen
Group 2 – Placebo + advice to take ibuprofen
Group 3 – Uva-ursi + no advice to take ibuprofen
Group 4 – Placebo + no advice to take ibuprofen
Patients and physicians will be blinded to the randomised group for the herb.
The main outcome is symptom severity at days 2–4 recorded in a validated, self-report diary used in previous studies.
Secondary outcomes include antibiotic use and symptom duration.
In total the trial will require 328 patients in order to achieve at least 90% power for the primary endpoint and 80% for
the secondary endpoint.
In accordance with CONSORT guidelines all comparative analyses will be conducted on an intention-to-treat basis
using SPSS or similar package.
Discussion: The outcomes from this trial have the potential to modify the current approach to the management of
acute urinary symptoms with less dependence on the use of antibiotics.
Trial registration: ISRCTN registry, ID: ISRCTN43397016. Registered on 11 February 2015.
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Background
Urinary tract infections (UTIs) are one of the most com-
mon conditions seen in female patients in general prac-
tice for whom the lifetime risk is 50% and the annual
incidence is estimated to be over 10% [1]. It accounts for
1–3% of all general practitioner (GP) consultations and
the majority of women (93%) are prescribed antibiotics
[2]. This strategy is poorly directed at women with
proven infection [3], although women with dipstick-
negative symptoms show evidence of shortened illness
duration following empirical antibiotic treatment [4].
Urine is now the most commonly received specimen in
microbiological laboratories, but more than 20% of iso-
lates are resistant to trimethoprim and cephalosporins
and 50% are resistant to amoxicillin [5]. Recent studies
have documented a worse prognosis and higher treat-
ment costs for women with UTI with antibiotic-resistant
organisms [2, 6], and antibiotic resistance in urine iso-
lates is linked to prior antibiotic exposure [7, 8]. How-
ever, limited data from trials suggest that uncomplicated
UTIs have a good long-term prognosis, with low risk of
complications [5, 9, 10]. Urinary symptoms usually settle
3–4 days after consultation but a shortened illness is ex-
perienced by women prescribed antibiotics in the ab-
sence of resistance [2, 11]. So, antibiotics do provide
some relief from the distressing symptoms of UTI [12],
but it is still unclear how best to target them or whether
alternative symptomatic treatments might reduce reli-
ance on antibiotics.
The delayed antibiotic prescription strategy results in a
substantial reduction in antibiotic prescribing rates in re-
spiratory illness and has gained credence as a rational
approach to management endorsed by NICE [12, 13]. In
respiratory illness it is considered to be a more effective
way to modify consultation behaviour than patient edu-
cation [14]. It has been shown to be acceptable to
women with cystitis but with only a modest reduction in
antibiotic use [15]. However, it is unlikely to be widely
adopted without an alternative treatment to relieve the
symptoms of infection. Two potential candidates have
been identified to provide such relief from symptoms. A
non-steroidal anti-inflammatory drug (NSAID) and a
herbal product with traditional use in UTI in women
which, if successful, could facilitate the adoption of the de-
layed strategy and further reduce antibiotic use in UTI.
Background to alternative treatments
NSAIDs
In one small study (n = 80) women with clinically sus-
pected urinary infection were randomised to treatment
with antibiotics or ibuprofen [16]. It was reported that
ibuprofen provided similar levels of symptom relief to
antibiotics (although this did not reach statistical signifi-
cance in this small study) but, as would be expected, a
larger proportion of women in the ibuprofen group re-
quired rescue antibiotics (33% versus 18%). A follow-up,
fully powered trial has subsequently confirmed a sub-
stantial (66%) reduction in antibiotic use (94/241 ibupro-
fen versus 283/243 antibiotic) [17], although symptom
burden was greater in the ibuprofen group: 70%
symptom-free after 1 week with ibuprofen compared to
82% in the antibiotic group. This suggests that NSAIDs
could reduce antibiotic use at the expense of poorer
symptom relief.
Herbal product
Herbal products for the relief of urinary symptoms are
widely available over-the-counter (OTC) with a traditional-
use licence, although they have never been subjected to
rigorous efficacy studies. The leaf extract of Arctostaphylos
uva-ursi (uva-ursi or bearberry) has been approved for use
for urinary tract inflammation by the German Federal In-
stitute for Drugs and Medical Devices and is available on
prescription in Germany for this indication. It is reported
to have diuretic, urinary antiseptic, astringent and anti-
inflammatory properties [18]. The extract constituents
include flavonoids, iridoids, hydroquinone glycosides
(mainly arbutin), tannins and terpenoids. In-vitro studies
have demonstrated antibacterial activity against a variety
of organisms including Escherichia coli, the most preva-
lent urinary pathogen. The antimicrobial action has been
attributed to the hydroquinone derivatives, especially
arbutin [18].
Uva-ursi is widely available OTC in the UK and there
is preliminary evidence suggesting that it provides symp-
tom relief when used in acute UTI. One study of 309
women found that those recommended to use Uvacin
(an OTC preparation including uva-ursi) experienced
shorter illness duration, although the numbers who sub-
sequently reported use of the product was low (14% with
advice to use versus 1% with no advice) [15]. There is
also some limited evidence that the prophylactic use of
UVA-E, containing an aqueous/alcoholic extract of
uva-ursi leaves and Taraxacum offinale (dandelion) root
(n = 57) is effective for women with recurrent UTI [19].
Main research question
The main study has two primary aims to assess the
impact on UTI symptom severity of:
1. Uva-ursi compared to placebo, and
2. Advice to take ibuprofen compared to no such advice
Our secondary research objectives are to:
1. Examine the impact on the use of antibiotics and
symptom duration
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2. Describe the patient/practitioner barriers to the
implementation of a delayed antibiotic prescription
approach, and
3. Ascertain attitudes to the use of herbal medication
Methods/design
Study design and setting
ATAFUTI is a multicentre, factorial (2 × 2), randomised,
double-blind, placebo-controlled trial of uva-ursi, and an
open, pragmatic trial of advice/no advice to take ibupro-
fen. UK patients access in-hours care largely through fam-
ily practices which hold registered patient lists; services
are also available from walk-in facilities where no prior
registration is needed and may be used for more acute
symptoms. Out-of-hours services are provided at a district
level from separately commissioned providers. Recruit-
ment will be conducted in up to 60 GP family practices,
walk-in centres and out-of-hours primary care practices
across the South Midlands, East Anglia, the South, South-
east and Southwest England. See Additional file 1 for a
completed Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) 2013 Checklist.
Group 1 – Uva-ursi + advice to take ibuprofen
Group 2 – Placebo + advice to take ibuprofen
Group 3 – Uva-ursi + no advice to take ibuprofen
Group 4 – No uva-ursi + no advice to take ibuprofen
The target population will be women presenting with
symptoms of uncomplicated acute cystitis to primary
care sites. All study centres will be selected from mem-
bers of the National Institute for Health Research
(NIHR) clinical research network related to three re-
cruitment centres (Southampton, Bristol and Oxford)
and who express an interest in the study.
Prior to participation all patients will be given a Par-
ticipant Information Sheet (PIS) detailing the study
protocol, and be required to give informed written con-
sent (IC). Those agreeing and who are eligible to take
part will need to provide a mid-stream urine specimen
for confirmation of bacteriuria at baseline. Amongst
women of child-bearing age a urine pregnancy test will
also be performed. A subsample (20%) will be asked to
provide a second urine sample after 4 days to be ana-
lysed for metabolites of uva-ursi (see Additional files 2,
3, 4 and 5 for the PIS and IC Forms for the main trial).
Patients will take the study medication for 3–5 days,
and will complete a symptom diary for up to 2 weeks
(see Additional file 6 for the diary). All participants will
be issued a prescription for delayed antibiotics to be
used if symptoms worsen, or after 3 to 5 days if symp-
toms fail to improve. A notes review will be undertaken
at 3 months to document GP consultations regarding a
recurrence of UTI.
Participants’ eligibility
Patients meeting the following criteria may be included
in the trial: female primary-care patients (aged 18–70
years) who, upon presenting to primary care with dys-
uria, urgency or frequency of urination, are suspected by
a GP or nurse practitioner to have a lower UTI. They
must be willing to accept a delayed prescription for anti-
biotics. Patients meeting any of the following exclusion
criteria will be excluded from the study: known or sus-
pected pregnancy; breastfeeding; suspected upper UTI
(presenting with back pain, fever > 38 °C, systemic
illness); who require immediate antibiotics; are within 7
days of taking antibiotics; frequent recurrent UTI (more
than three UTI episodes in the past 12 months); known
contraindications or cautions to ibuprofen; using an
NSAID or taking an uva-ursi preparation and unwilling
or unable to discontinue for the study period; diabetes;
an immunodeficiency state and taking long-term corti-
costeroids or chemotherapy; bladder surgery including
cystoscopy in the last 4 weeks; currently taking warfarin,
or coagulopathy; recruited to another trial in the previ-
ous 4 weeks.
Recruitment and randomisation
Eligible participants will be identified and approached in
primary care centres (Fig. 1). The patient’s consent to
participate in the trial will be obtained prior to any trial-
related procedures, which includes pregnancy testing
and after a full explanation of the treatment options has
been given. Consent will be taken by an appropriately
trained research nurse or delegate. Patients who decline
to participate in the main study, as well as participants
who enter the main study, will be asked whether they
consent to the storage of their contact details so that a
qualitative researcher may contact them to invite them
to participate in a qualitative interview about views on
herbal treatment and potential barriers to study partici-
pation. The qualitative researcher will collect consent for
conducting the interview immediately prior to com-
mencement of the interview using the qualitative inter-
view Consent Form.
Patients who are eligible for the study will be ran-
domly assigned to one of the four treatment arms
through allocation of the next available sequentially
numbered ‘Patient Pack’, with participants and clinicians
blinded to the uva-ursi groups. The Patient Pack number
will determine their Participant ID. Advice leaflets sup-
porting use of ibuprofen will be contained within treat-
ment packs and not visible prior to randomisation.
Recruiting practitioners will endorse ibuprofen use only
when directed after opening the pack, no ibuprofen will
be provided in the pack but patients randomised to the
ibuprofen groups will be given a card stating the dosing
regimen to be followed. The recruiting practitioners will
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be free to prescribe ibuprofen, but for participants paying
prescription charges a less costly option would be to pur-
chase a supply of ibuprofen from a pharmacy. No further
contact with the participant by the recruiting physician
will be specified, repeat consultations arising from clinical
need will be collected by independent note review. Out-
come assessors will also be blind to allocation of the herb
but advice and prescription of ibuprofen will be available
in the notes at the time of notes review. The randomisa-
tion concealment list will be produced centrally by the
Southampton Clinical Trials Unit and allocation ratio for
control to intervention arms will be 1:1.
Study interventions
The Investigational Medicinal Product (IMP) will com-
prise uva-ursi extract containing 20% arbutin supplied
by Temmler Pharma GmbH & Co (Germany), encapsu-
lated to Good Manufacturing Practice (GMP) and IMP
standards by Essential Nutrition Limited (UK). To main-
tain blinding, the matching placebo will contain sugar
beet fibre (Fibrex®), an inert substance with a similar
colour and a herbal flavour, from Nordic Sugar
(Denmark). The trial medication will be stored and
dispensed centrally in accordance with Good Clinical
Practice (GCP), and supplied in a medication securitai-
ner contained in a Patient Pack with instructions for the
GP to give advice or not to take ibuprofen.
The daily dose of uva-ursi, which has been submitted
to, and approved by, the Medicines and Healthcare
Regulatory Committee (MHRA), will be 3600 mg (3 ×
400-mg capsules) to be taken orally three times a day
thus providing a total of 686 mg arbutin. Participants
will be asked to take the study medication for 3 days
and up to 5 days. A prescription for rescue antibiotics
will be made available for all participants with instruc-
tions to take if adequate symptom relief is not obtained
from the study medication.
A structured Advice Sheet and a card detailing the
ibuprofen dose and approved medication will be pro-
vided to participants randomised to the ibuprofen arm.
A daily dose of 1200 mg, to match the dose used in the
previous trials [16, 17], will be recommended or pre-
scribed on request. The group not randomised to the
ibuprofen arm will not receive any advice on this drug.
The intervention is advice only and falls outside regula-
tion by the MHRA.
Assessment and follow-up
Participants will be required to maintain a daily symp-
tom diary used in previous studies of UTI [20, 21], grad-
ing severity of their presenting and subsequent UTI
symptom(s). To assist completion they will be contacted
by a research assistant after 3 days. No questions will be
asked about compliance or delayed prescription. Com-
pleted diaries will be returned to the Southampton
Fig. 1 Recruitment and randomisation
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Centre in a freepost envelope. In the event of non-
return after 3 weeks participants will be contacted to
prompt diary return or complete a brief symptom inven-
tory using recall if the diary is mislaid.
Symptom severity for the primary outcome will be re-
corded in the symptom diary where day 1 is completed
on the day of the consultation. Previous factor analysis
of the diary has shown that symptoms can be grouped
into two factors, ‘frequency’ and ‘unwell’ symptoms [2].
The primary outcome consists of the mean symptom
score of the ‘frequency factor’ items on days 2–4 follow-
ing consultation on day 1.
Primary outcome:
Symptom severity on days 2–4 using validated diary
data [2, 15, 22].
Secondary outcomes:
Use of antibiotics
Individual data from each of the four groups for
primary outcome and use of antibiotics
Duration of moderately bad symptoms
Duration of symptoms until little or no problem
Total symptom burden derived from diary data
Re-consultation in 1 month with UTI from notes review
Re-consultation in 3 months with UTI from notes review
Exploratory analysis:
Differential effects on primary outcome depending on
culture results
Adverse events will be recorded as detailed below
under safety considerations.
Data and all appropriate documentation will be stored for
a minimum of 5 years after the completion of the trial, in-
cluding the follow-up period. The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) Figure
showing the schedule for enrolment, interventions and as-
sessments is provided in Fig. 2.
Qualitative interviews
Attitudes towards the delayed prescribing of antibiotics
in favour of treating the symptoms with ibuprofen and/
or herbal medicine will be explored in a nested qualita-
tive study. In-depth semistructured telephone interviews
will be conducted amongst 20–30 women who have
taken part in the trial or who were approached but not
randomised, and amongst 10–15 GPs from the same GP
practices. Participants will be given an invitation letter, a
PIS and a Consent Form to be signed and returned to
the researcher, who will contact them about a month,
but no more than 3 months, after taking part (see
Additional files 7, 8, 9 and 10 for the PIS and IC Forms).
Interviews will be conducted using an interview schedule,
will be 15–30 min in duration and will be recorded and
transcribed verbatim. All interviews will be analysed using
thematic analysis [23], facilitated by NVivo software.
Safety considerations and withdrawal
The discontinuation of study medication will occur if
there is evidence of progressive infection or upper urin-
ary tract symptoms which warrant immediate antibiotic
therapy, pregnancy, any development of toxicity, or a
concurrent illness in which the investigator’s opinion
precludes further treatment. Participants are all provided
with a prescription for rescue medication and are able to
self-determine when to collect the prescription depend-
ing on symptom burden and whether to continue or
stop the study medication(s).
Most adverse events (AEs) and adverse drug reactions
that occur in this trial, whether serious or not, are antici-
pated to be expected treatment-related toxicities due to
the trial medication. The assignment of the causality will
be made by the primary care physician responsible for
the participant. A pre-existing condition will not be re-
ported as an AE unless the condition worsens by at least
one Common Terminology Criteria for Adverse Events
grade during the trial.
A major concern over the withholding of antibiotics is
the potential for progressive infection and upper UTI.
There are, however, limited data regarding the absolute
risk of upper tract infection following lower tract infec-
tion in women. In a meta-analysis of placebo versus anti-
biotic trials, antibiotics were more effective than placebo
but associated with more adverse effects [11]. In the two
trials that reported the incidence of pyelonephritis, the
range in those treated with antibiotics was 0–0.15% and
in those treated with placebo 0.4–2.6% (not significant).
In the recent trial of ibuprofen versus antibiotic [17] the
number of episodes of pyelonephritis was five in the
placebo arm compared to one in the antibiotic arm
although none required hospital admission. A similar
trend was noted for worsening symptoms and febrile
UTIs. Episodes of suspected upper UTI will be reported
and all AEs will be recorded from the time that the
patients signs the Consent Form until 4 weeks after
randomisation.
Notification of adverse events will be through one of
three mechanisms: (1) all participants will carry a trial
card with relevant telephone numbers to call should an
AE occur, (2) GP practices will notify the study team of
any AE reported to the practice and (3) AE information
will be collected at notes review after 3 months.
Due to the low risk of the IMP treatments and that
any emergency clinical decisions would be unaffected by
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knowledge of the treatment group, a normal-working-
hours unblinding service will be provided.
Participants are also free to withdraw at any time with-
out giving a reason.
All AEs that may be related to the study will be
recorded on the Adverse Events Form and sent to the
SCTU within 1 month of the form being due. As adults
on average see their GP approximately five times per
year for a variety of routine and unscheduled appoint-
ments (e.g. for medication review, self-limiting minor
illnesses and long-term conditions unrelated to urinary
infection), many medical encounters are of no
relevance to the study. Events that will be reported in-
clude any judged by the principal investigator at the
site to be possibly related to the study. In particular, all
medical encounters related to the following medical
areas or symptoms will be recorded in the Adverse
Events Form:
Abdominal symptoms: any events relating to abdominal
discomfort or other symptoms
Urine infection: any events relating to UTI
Medication: any events relating to study medication
The practitioners providing care for the patient are ad-
vised to record any event for which there is uncertainty
as to whether it is study-related or not, and to discuss
with the local principal investigator (PI) or chief investi-
gator (CI).
Fatal or life-threatening serious adverse events (SAEs)
and suspected unexpected serious adverse reactions
(SUSARs) will be reported within 24 h of the local site
becoming aware of the event. The SAE/SUSAR Form
asks for nature of event, date of onset, severity, correct-
ive therapies given, outcome and causality (i.e. unrelated,
unlikely, possible, probably, definitely) as per standard
reporting procedures.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure showing schedule of procedures (enrolment, intervention
and assessments)
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Power calculation and statistical analysis
In our previous study, the severity of frequency symptoms
at 2–4 days was 2.15 (SD 1.18) in the immediate antibiotic
group and 2.11 (mean difference −0.04, CI −0.47 to 0.40)
in the delayed antibiotic group [15]. The clinically signifi-
cant change in symptom severity based on previous con-
sensus [21] and the previous UTI study would be a
difference of 1 severity point in every two women, that is a
mean severity difference of 0.5. In order to estimate the
required sample size a power calculation was carried out
using NQuery 3.0 with a two-sided significance level of
5% (alpha = 0.05) and power of 90% (beta = 0.1) based on
a two-group t test of equal means. For the 2 × 2 factorial
design, to detect a mean severity difference of 0.5 with SD
1.18 requires a sample of 60 per group, or 75 per group,
so 300 in total allowing for 20% loss to follow-up.
An important secondary outcome is the proportion of
participants who use antibiotics. In our previous study
we achieved a reduction from 90% in the immediate
antibiotic group to 77% 41/53 in the delayed group
(without additional symptom relief ). Thus, in this study
we would anticipate the ‘placebo/no advice to take ibu-
profen arm’ to experience 77% uptake of antibiotic. In a
study comparing NSAID to antibiotic for UTI, only 33%
of the NSAID group required rescue antibiotics so po-
tentially this intervention may reduce antibiotic uptake
to as little as 30%. A clinically significant reduction in
antibiotic use would be 17% (i.e. from 77% to 60%) and
would require a total sample of 65.5 per group or 262 in
total, 328 allowing for 20% loss to follow-up (82 per
group) for 80% power with a two-sided significance level
of 5%, based on a chi-squared test of equal proportions.
In order to achieve at least 90% power for the primary
endpoint and allowing 20% loss to follow-up, the trial re-
quires four groups of 82 patients. If the loss to follow-up
is higher than anticipated and increases to 30%, a total of
376 patients (94 per group) will be required. The trial is
not powered for any interaction between factorial groups.
Statistical analysis
All analyses will be performed on a full intention-to-
treat basis, that is, all patients randomised will be in-
cluded, and all patients will be analysed according to
their allocated group whatever treatment they receive.
For the primary analyses, descriptive statistics will be ob-
tained for the randomisation groups to characterise re-
cruited patients and assess baseline comparability. The
study will be reported in accordance with Consolidated
Standards of Reporting Trials (CONSORT) guidelines [22].
For the primary outcome, analysis of covariance will
be used to analyse symptom-severity data with imput-
ation of missing data. Logistic regression will be used to
analyse the dichotomous outcomes (antibiotic use, re-
consultation in 1 month with UTI and re-consultation
with UTI from notes review in the next 12 months).
Negative binomial regression will be used to analyse dur-
ation of moderately bad symptoms. All analyses will be
adjusted for the factorial design and, if necessary, for po-
tential confounding variables, e.g. use of antibiotics.
For each outcome the following pairwise comparisons
will be examined by calculating a 95% CI for the differ-
ence/odds ratio/incidence rate ratio:
1. Uva-ursi versus no uva-ursi: group 1 + group 3
patients versus group 2 + group 4 patients
2. Advice to take ibuprofen versus no advice to take
ibuprofen: group 1 + group 2 patients versus group
3 + group 4 patients
In a previous observational cohort, the exploratory fac-
tor analysis of the severity of symptoms demonstrated two
groups of symptoms: these were increased day frequency,
increased night frequency and urgency and dysuria (a
‘frequency’ group of symptoms; Cronbach’s alpha = 0.77);
and abdominal pain, restricted activities and feeling unwell
(‘unwell’ group of symptoms; Cronbach’s alpha = 0.80). We
will explore the effect of the interventions on symptoms
in the frequency and unwell clusters.
The Data Monitoring Committee will review safety
and efficacy data at least annually. Data management is
directed by the standard operating procedures of the
Southampton University CTU.
The main analysis will be carried out when all patients
have completed the study. A statistical analysis plan will
be written before the data are analysed.
Discussion
The ATAFUTI study is the first double-blind, placebo-
controlled, factorial randomised trial to investigate a
traditional herbal medicinal product as an alternative
treatment for UTIs in women, with the aim of reducing
symptoms and reducing antibiotic consumption in pri-
mary care. The open, pragmatic arm of the trial also
builds on existing research into symptom relief of un-
complicated UTI with ibuprofen, whereby two thirds of
women (n = 248) with mild to moderate symptoms re-
covered without the need for antibiotics [17]. It will pro-
vide clinical evidence on the efficacy and safety of using
ibuprofen and a traditional herbal medicine uva-ursi, ei-
ther singularly or in combination for the relief of the dis-
tressing symptoms of UTI in women, one of the most
common reasons for antibiotic prescription. The NSAID
has known anti-inflammatory properties, and uva-ursi
has demonstrated antibacterial properties against E. coli
both in vitro as well as in urine samples of healthy vol-
unteers [18].
The diary format has been previously validated and
shown to be sensitive to change for other acute
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infections [22, 24]. By using this method it will allow the
impact of the intervention on symptom severity and on
the duration of symptoms to be investigated.
Should the main outcome of the trial be positive, the
qualitative element of the study will provide insights into
any reservations that patients and practitioners may have
about accepting a recommendation/prescription for ibu-
profen and/or uva-ursi, with delayed prescribing of anti-
biotics, which in turn will inform implementation of the
findings. The finding will be disseminated by publication
and presentation at conferences. Summary findings will
be provided to participating practices.
Trial status
Recruitment commenced in August 2015 and is due to
complete by October 2016.
The study has been reviewed by the NHS Health Re-
search Authority: South Central Hampshire A 14/SC/1143.
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